IBB logo

IBBiShares Biotechnology ETF

$170.66
$0.17
(0.10%)
Today
Closed $170.66
$0.00
(0.00%)
After Hours
Updated: 04:10 PM EDT
Vol1.7M
52W High$179.64
52W Low$123.61
News
all
press releases
Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market
GLP-1 drugs are reshaping healthcare and consumer markets. These ETFs offer targeted exposure to the booming obesity-drug trend.
Zacks
News Placeholder
More News
News Placeholder
ABVX Stock Clocks Worst Day Ever On Malignancy Signal For Drug: ‘Pharma Bro’ Says ‘GLPs Are Doing Fine’ After Similar Fears
Shares of ABVX closed down 44% on Tuesday, clocking its worst day ever, on reports of a number of non-melanoma skin cancers and other malignancies observed in its ulcerative colitis trial.
Stocktwits
News Placeholder
ABVX Tanks 30% After-Hours Despite 51% Remission In Ulcerative Colitis Trial — Rare Cancer Concerns Hit Sentiment
The company dismissed the cancers observed in the trial as rare, occurring primarily in older patients, and largely unrelated to treatment.
Stocktwits
News Placeholder
GILD Stock Jumps After Winning Accelerated FDA Approval For HDV Treatment
U.S. Food and Drug Administration (FDA) approved Hepcludex (bulevirtide-gmod) injection to treat chronic hepatitis delta virus.
Stocktwits
News Placeholder
ONC Stock Gains As BeOne Medicines Wins US Nod For BEQALZI In Rare Lymphoma
The FDA approved BEQALZI in the treatment of certain mantle cell lymphoma patients on Wednesday.
Stocktwits
News Placeholder
ABCL Stock Clocks Best Week Since February On Clinical Data Anticipation, Baker Bros Stake Boost
On Monday, AbCellera will release its financial results alongside interim early-stage data for its lead internal candidate ABCL635.
Stocktwits
News Placeholder
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
Smart Beta ETF report for IBB
Zacks
News Placeholder
CMPS On Track For Best Week Ever On FDA Push For Psychedelics
Compass said on Friday that the FDA has granted its synthetic psilocybin formulation the Commissioner's National Priority Voucher for treatment-resistant depression.
Stocktwits
News Placeholder
KYTX Stock Soars After Hours: What’s Driving The Rally?
Kyverna reported strong pivotal trial results for its one-time CAR-T therapy miv-cel, showing rapid mobility improvements and reversal of disability in patients with stiff person syndrome.
Stocktwits
News Placeholder
Should You Invest in the iShares Biotechnology ETF (IBB)?
Sector ETF report for IBB
Zacks
<
1
2
...
>

Advertisement|Remove ads.